Jaume Sastre-Garriga
Overview
Explore the profile of Jaume Sastre-Garriga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
173
Citations
3449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marrodan M, Sao Aviles A, Rio J, Cobo-Calvo A, Fernandez V, Pappolla A, et al.
Mult Scler
. 2025 Feb;
:13524585251316471.
PMID: 39925147
Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and...
2.
Vilaseca A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, Arevalo M, Arino H, et al.
Mult Scler
. 2025 Feb;
:13524585251314749.
PMID: 39907218
Background: It is essential to exclude alternative diagnoses to diagnose multiple sclerosis (MS). However, detailed descriptions of alternative diagnoses in patients with suspected MS presenting with clinically isolated syndrome (CIS)...
3.
Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, et al.
Neurology
. 2025 Feb;
104(4):e210305.
PMID: 39903901
Background And Objectives: Emerging concepts in the early detection of multiple sclerosis (MS) progression reveal that disability accumulation can start early in the disease course. Aging in MS is increasingly...
4.
Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Aviles A, Arrambide G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200370.
PMID: 39879564
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP),...
5.
Boaventura M, Fragoso D, Avolio I, Pereira S, Callegaro D, Sato D, et al.
J Neurol
. 2025 Jan;
272(2):157.
PMID: 39821642
Background: The presence of diffuse brain damage in normal-appearing white matter (NAWM) and gray matter (NAGM) in neuromyelitis optica spectrum disorder (NMOSD) remains controversial. We aimed to address this controversy...
6.
Sastre-Garriga J, Graves J, Ontaneda D, Rocca M, Chard D, Toosy A, et al.
Mult Scler
. 2025 Jan;
31(1):3-5.
PMID: 39784932
No abstract available.
7.
Marti-Juan G, Sastre-Garriga J, Vidal-Jordana A, Llufriu S, Martinez-Heras E, Groppa S, et al.
Netw Neurosci
. 2024 Dec;
8(4):1545-1562.
PMID: 39735510
Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system. Structures affected in MS include the corpus callosum, connecting the hemispheres. Studies have shown that in mammalian...
8.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
9.
Mongay-Ochoa N, Pareto D, Alberich M, Carbonell-Mirabent P, Valsasina P, Margoni M, et al.
Neurology
. 2024 Dec;
104(1):e210136.
PMID: 39666921
Background And Objectives: In multiple sclerosis (MS), brain reserve serves as a protective factor against cognitive impairment. Previous research has suggested a structural counterpart in the spine-spinal cord reserve-seemed to...
10.
Comabella M, Hegen H, Villar L, Rejdak K, Sao-Aviles A, Behrens M, et al.
J Neurol
. 2024 Dec;
272(1):26.
PMID: 39666032
Background And Objectives: The impact of viral infections on disease susceptibility and progression has predominantly been studied in patients with relapse-onset MS (RMS). Here, we determined immune responses to ubiquitous...